Ascorbic Acid 0.025% | Hydroquinone 6% | Tretinoin 0.01% | Triamcinolone 0.1%

Applied topically as a thin layer to affected hyperpigmented areas of the face or skin. This formulation is intended for prescriber-directed application per the following guidance:

• Apply a thin film to affected areas at night (typically at bedtime) as directed by the prescriber.
• Cleanse and dry the area before application. Avoid contact with eyes, nostrils, mouth, and mucous membranes.
• Wash hands before and after application.
• Use sunscreen daily (SPF 30+) during treatment — tretinoin and hydroquinone increase photosensitivity.
• Avoid applying to broken, irritated, or sunburned skin.

Dosing frequency and duration are prescriber-determined based on the degree of hyperpigmentation, skin type, and tolerability. General principles include:

• Typically applied once nightly to affected areas; the prescriber may specify alternate-day application during an initiation period to limit retinoid irritation.
• Initial courses are often 8–12 weeks; maintenance schedules vary by clinical response and prescriber judgment.
• If significant irritation or exogenous ochronosis develops, the prescriber should be consulted before continuing.
• Strict daily photoprotection (broad-spectrum SPF 30+) is required throughout treatment to prevent UV-driven re-pigmentation.
• Do not exceed the prescribed application frequency; prolonged or heavy use of the triamcinolone component carries risk of cutaneous atrophy.

• Ascorbic Acid: Chelates copper from the tyrosinase active site and scavenges reactive oxygen species, reducing the oxidative step in melanin biosynthesis.
• Hydroquinone: Competitively inhibits tyrosinase, blocking conversion of DOPA to dopaquinone; also degrades melanosomes, inhibits melanocyte mitochondrial enzymes, and at 6% concentration may directly damage melanocytes.
• Tretinoin: Binds retinoic acid receptors (RAR-α, RAR-γ), stimulating keratinocyte proliferation and differentiation, accelerating desquamation of melanin-containing cells from the epidermis, and enhancing co-ingredient penetration through the stratum corneum.
• Triamcinolone: Binds cytoplasmic glucocorticoid receptors, translocates to the nucleus, and suppresses pro-inflammatory cytokines and tyrosinase expression in melanocytes, attenuating post-inflammatory pigment induction.

This modified Kligman formulation is prescribed for the management of melasma, post-inflammatory hyperpigmentation (PIH), and other disorders of epidermal hypermelanosis. Clinical considerations include:

• The 6% hydroquinone concentration is above the standard commercial OTC limit (2%) and requires a prescription; prescribers should document clinical rationale for this strength.
• Monitor for exogenous ochronosis — paradoxical blue-black skin darkening associated with prolonged high-concentration hydroquinone use; discontinue if this develops.
• Tretinoin-induced retinoid dermatitis (erythema, scaling, peeling) is expected in the first 2–4 weeks; use of a non-comedogenic moisturizer and dose tapering may improve tolerability.
• Triamcinolone 0.1% is a medium-potency Class III corticosteroid; limit continuous facial application to avoid cutaneous atrophy, telangiectasia, and HPA axis suppression.
• Fitzpatrick skin types IV–VI may be at higher risk of paradoxical post-inflammatory hyperpigmentation if irritation occurs; consider initiating at reduced frequency.
• Monthly follow-up for 3 months recommended to assess response, tolerability, and skin integrity.

Contraindications:

• Hypersensitivity to hydroquinone, tretinoin, triamcinolone, or any component of the formulation.
• Rosacea, perioral dermatitis, or acne rosacea (corticosteroid component may exacerbate).
• Viral, fungal, or bacterial cutaneous infections in the treatment area.
• Pregnancy: Tretinoin is Pregnancy Category C (topical); avoid unless clearly indicated. Hydroquinone systemic absorption in pregnancy is poorly characterized.

Warnings & Precautions:

• Exogenous ochronosis risk with prolonged high-dose hydroquinone use; limit continuous use duration per prescriber direction.
• Topical corticosteroid side effects with prolonged use: skin atrophy, striae, telangiectasia, hypertrichosis, and perioral dermatitis.
• Photosensitivity: tretinoin significantly increases UV sensitivity; strict sun avoidance and SPF 30+ required.
• Avoid contact with mucous membranes, eyes, and lips.

Drug Interactions:

• Concurrent use of other retinoids, benzoyl peroxide, or keratolytics increases irritation risk.
• Photosensitizing drugs (fluoroquinolones, tetracyclines, thiazides) may compound tretinoin-related photosensitivity.

Common Side Effects: Erythema, peeling, dryness, burning sensation, and initial worsening of pigmentation during the retinoid initiation phase; skin lightening at the site of application.

Store at controlled room temperature (15–25°C / 59–77°F), away from heat, light, and humidity. Do not refrigerate unless specifically directed. Retinoids and hydroquinone are photosensitive; keep in original opaque container. Keep out of reach of children. Use by the beyond-use date (BUD) assigned per USP <795> compounding standards. Discard if discoloration, phase separation, or odor change occurs.

Is this the same as Tri-Luma or other FDA-approved products?

No. This is a compounded, patient-specific preparation distinct from FDA-approved triple-combination creams. The specific ingredient concentrations in this formulation differ from commercially available products and are determined by the prescribing clinician based on individual patient need. It is not FDA-approved as a compounded preparation.

Why does my skin peel and turn red initially?

Tretinoin stimulates rapid keratinocyte turnover, which commonly causes retinoid dermatitis — erythema, scaling, and peeling — particularly in the first 2–4 weeks. This typically subsides as the skin acclimates. A non-comedogenic moisturizer and reduction in application frequency may help; notify your prescriber if irritation is severe.

Why is sunscreen essential during treatment?

Tretinoin thins the stratum corneum and increases photosensitivity, making the skin more vulnerable to UV-induced re-pigmentation. Daily broad-spectrum sunscreen (SPF 30 or higher) is critical to prevent reversal of therapeutic gains.

What is exogenous ochronosis, and should I be concerned?

Exogenous ochronosis is a paradoxical blue-black skin darkening caused by prolonged use of high-concentration hydroquinone, particularly in darker skin types. Your prescriber will monitor for this during follow-up; report any unusual darkening of treated areas promptly.

How long before I see results?

Visible improvement in hyperpigmentation typically requires 8–12 weeks of consistent nightly application combined with strict photoprotection. Premature discontinuation often results in relapse; maintenance protocols will be determined by your prescriber.